Trial Profile
Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif New Formulation (REFLEXION)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms REFLEXION
- Sponsors Merck KGaA; Merck Serono
- 15 Oct 2021 Results of an analysis assessing the temporal relation between whole-brain atrophy and lesion processes presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 01 May 2020 Results, assessing data from ( REFLEX and REFLEXION) assessing pharmacodynamic biomarkers of Interferon beta 1a, presented at the 72nd Annual Meeting of the American Academy of Neurology
- 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.